The new concept of interventional heart failure therapy-part 1: Electrical therapy, treatment of CAD, fluid removal, and ventricular support

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 15, Issue 2, 2010, Pages 102-111

  Thompson, Keith A ^a   Philip, Kiran J ^a   Barbagelata, Alejandro ^a   Schwarz, Ernst R ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Heart failure; Surgical ventricular restoration; Ultrafiltration

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIURETIC AGENT; FENOLDOPAM;

BRADYCARDIA; CARDIAC CONTRACTILITY MODULATION; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOMYOPLASTY; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DILATATION; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; DEFIBRILLATION; DRUG EFFICACY; ELECTROSTIMULATION THERAPY; HEART ASSIST DEVICE; HEART CATHETERIZATION; HEART DEATH; HUMAN; HYPERVOLEMIA; HYPOTENSION; HYPOVOLEMIA; INFUSION SYSTEM; INTERMETHOD COMPARISON; INTERVENTIONAL CARDIOVASCULAR PROCEDURE; ISCHEMIC HEART DISEASE; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REVIEW; TREATMENT INDICATION; TREATMENT OUTCOME; ULTRAFILTRATION; VAGUS NERVE STIMULATION; HEART FAILURE; HEART MUSCLE CONDUCTION SYSTEM; HEART SURGERY; HEART VALVE; HEART VENTRICLE; METHODOLOGY; PATHOPHYSIOLOGY; UNITED STATES;

CARDIAC SURGICAL PROCEDURES; CORONARY ARTERY DISEASE; HEART CATHETERIZATION; HEART CONDUCTION SYSTEM; HEART FAILURE; HEART VALVES; HEART VENTRICLES; HEART-ASSIST DEVICES; HUMANS; UNITED STATES; VAGUS NERVE STIMULATION;

EID: 77951891020     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248410366447     Document Type: Review

References (63)

1. Lloyd-Jones D., Adams R., Carnethon M., et al. Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009 ; 119 (3). e21 - e181.
2. Jessup M., Abraham W., Casey DE, et al. 2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in Collaboration With the International Society of Heart and Lung Transplantation. Circulation. 2009 ; 119 (14). 1977-2016.
3. Cohn JN, Johnson G., Ziesche S., et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991 ; 325 (5). 303-310.
4. Garg R., Yusuf S. Overview of randomized trials of angiotensin converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA. 1995 ; 273 (18). 1450-1456.
5. Pitt B., Remme W., Zannad F., et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003 ; 348 (14). 1309-1321.
6. Hjalmarson A., Goldstein S., Fagerberg B., et al. Effects of controlled release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). JAMA. 2000 ; 283 (10). 1295-1302.
7. Packer M., Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure: U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996 ; 334 (21). 1349-1355. (Pubitemid 26152713)
8. Packer M., Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001 ; 344 (22). 1651-1658. (Pubitemid 32479962)
9. Faris R., Flather M., Purcell H., Henein M., Poole-Wilson P., Coats A. Current evidence supporting the role of diuretics in heart failure: a meta-analysis of randomized controlled trials. Int J Cardiol. 2002 ; 82 (2). 149-158.
10. Taylor AL, Ziesche S., Yancy C., et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004 ; 351 (20). 2049-2057.
11. Colucci WS, Elkayam U., Horton DP, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N Engl J Med. 2000 ; 343 (4). 246-253.
12. DiBianco R., Shabetai R., Kostuk W., Moran J., Schlant RC, Wright R. A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure. N Engl J Med. 1989 ; 320 (11). 677-683.
13. Dobbs SM, Kenyon WI, Dobbs RJ Maintenance digoxin after an episode of heart failure: placebo-controlled trial in outpatients. Br Med J. 1977 ; 1 (6063). 749-752.
14. Lee DC, Johnson RA, Bingham JB, et al. Heart failure in outpatients: a randomized trial of digoxin versus placebo. N Engl J Med. 1982 ; 306 (12). 699-705.
15. Guyatt GH, Sullivan MJ, Fallen EL, et al. A controlled trial of digoxin in congestive heart failure. Am J Cardiol. 1988 ; 61 (4). 371-375.
16. The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. N Engl J Med. 1997 ; 336 (8). 525-533.
17. Mancini D., Burkhoff D. Mechanical device-based methods kof managing and treating heart failure. Circulation. 2005 ; 112 (3). 438-448.
18. Moss AJ, Zareba W., Hall J., et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002 ; 346 (12). 877-883.
19. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005 ; 352 (20). 225-237.
20. Kadish A., Dyer A., Daubert JP, et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. 2004 ; 350 (21). 2151-2158.
21. Abraham WT, Fisher WG, Smith AL, et al. Cardiac resynchronization in chronic heart failure. N Engl J Med. 2002 ; 346 (24). 1845-1853.
22. Zipes DP, Rubart M. Mechanisms of sudden cardiac death. J Clin Invest. 2005 ; 115 (9). 2305-2315.
23. Ghanbari H., Dalloul G., Hasan R., et al. Effectiveness of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death in women with advanced heart failure: a meta-analysis of randomized controlled trials. Arch Intern Med. 2009 ; 169 (16). 1500-1506.
24. Bristow MR, Saxon LA, Boehmer J., et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004 ; 350 (21). 2140-2150.
25. McAlister FA, Ezekowitz J., Hooton N., et al. Cardiac resynchronization therapy for patients with left ventricular systolic dysfunction: a systematic review. JAMA. 2007 ; 297 (22). 2502-2514. (Pubitemid 46953404)
26. Moss AJ, Hall WJ, Cannom DS, et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med. 2009 ; 361 (14). 1329-1338.
27. Chung ES, Leon AR, Tavazzi L., et al. Results of the Predictors of Response to CRT (PROSPECT) trial. Circulation. 2008 ; 117 (20). 2608-2616.
28. Epstein AE, Dimarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation. 2008 ; 117 (21). e350.
29. Brunckhorst CB, Shemer I., Mika Y., Ben Haim SA, Burkhoff D. Cardiac contractility modulation by non-excitatory currents: studies in isolated cardiac muscle. Eur J Heart Fail. 2006 ;(8). 7-15.
30. Burkhoff D., Shemer I., Felzen B., et al. Electric currents applied during the refractory period can modulate cardiac contractility in vitro and in vivo. Heart Fail Rev. 2001 ; 6 (1). 27-34.
31. Mohri S., He KL, Dickstein M., et al. Cardiac contractility modulation by electric currents applied during the refractory period enhances contractility and systolic calcium in ferret. Am J Physiol Heart Circ Physiol. 2002 ; 284 (4). 119-123.
32. Butter C., Rastogi S., Minden HH, Meyhofer J., Burkhoff D., Sabbah HN Cardiac contractility modulation electrical signals improve myocardial gene expression in patients with heart failure. J Am Col Cardiol. 2008 ; 51 (18). 1784-1789.
33. Imai M., Rastogi S., Gupta RC, et al. Therapy with cardiac contractility modulation electric signals improves left ventricular function and remodeling in dogs with chronic heart failure. J Am Coll Cardiol. 2007 ; 49 (21). 2120-2128.
34. Borgreffe M., Lawo T., Butter C., et al. Randomized, double-blind study of non-excitatory, cardiac contractility modulation electrical impulses for symptomatic heart failure. Eur Heart J. 2008 ; 29 (8). 1019-1028.
35. Abraham WT, Burkhoff D., Nademanee K., et al. Multicenter randomized controlled trial of cardiac contractility modulation in patients with advanced heart failure. American College of Cardiology 58th Annual Scientific Session ; 2009.
36. Li M., Zheng C., Sato T., Kawada T., Sugimachi M., Sunagawa K. Vagal nerve stimulation markedly improves ling-term survival after chronic heart failure in rats. Circulation. 2004 ; 109 (1). 120-124.
37. Schwartz PJ, De Ferrari GM, Sanzo A., et al. Long term vagal stimulation in patients with advanced heart failure first experience in man. Eur J Heart Fail. 2008 ; 10 (9). 884-891.
38. De Ferrari GM Chronic vagus nerve stimulation: a new treatment modality for congestive heart failure. Proceedings of the 58th Annual Scientific Session of American College of Cardiology. 2009.
39. De Ferrari GM, Sanzo A., Schwartz PJ Chronic vagal stimulation in patients with congestive heart failure. Conf Proc IEEE Eng Med Biol Soc. 2009 ; 2009: 2037-2039.
40. Gheorghiade M., Bonow RO Chronic heart failure in the United States: a manifestation of coronary artery disease. Circulation. 1998 ; 97 (3). 282-289. (Pubitemid 28067315)
41. Smith SC, Allen J., Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation. 2006 ; 113 (22). 2363-2372. (Pubitemid 43947981)
42. Eagle KA, Guyton RA, Davidoff R., et al. ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Surgery). J Am Coll Cardiol. 2004 ; 44 (5). e213 - e311.
43. Taggart DP, Kaul S., Boden WE, et al. Revascularization for unprotected left main stem coronary artery stenosis. J Am Coll Cardiol. 2008 ; 51 (9). 885-892.
44. Serruys PW, Morice MC, Kappetein AP, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med. 2009;360(10):961-972. 45.
45. Daemen J, Wenaweser P, Tsuchida K, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet. 2007;369(9562):667-678. 46.
46. Mauri L, Hsieh WH, Massaro JM, Ho KK, Dg?Agostino R, Cutlip DE. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med. 2007;356(10):1020-1029. 47.
47. Smith SC, Feldman TE, Hirshfeld JW, et al. ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention-Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). J Am Coll Cardiol. 2006;47(1):216-235.
48. Teirstein P., Price M., Mathur V., Madyoon H., Sawhney N., Baim D. Differential effects between intravenous and targeted renal delivery of fenoldopam on renal function and blood pressure in patients undergoing cardiac catheterization. Am J Cardiol. 2006 ; 97 (7). 1076-1081.
49. Wertman B., Gura V., Schwarz ER Ultrafiltration for the management of acute cecompensated heart failure. J Cardiac Fail. 2008 ; 14 (9). 754-759.
50. Costanzo MR, Guglin ME, Saltzberg MT, et al. Ultrafiltration vursus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol. 2007 ; 49 (6). 675-683. 51. Acker MA Dynamic cardiomyoplasty: at the crossroads. Ann Thorac Surg. 1999 ; 68 (2). 750-755.
51. Chachques JC, Marino JP, Lajos P., et al. Dynamic cardiomyoplasty: clinical-follow up at 12 years. Eur J Cardio-thorac Surg. 1997 ; 12 (4). 560-568.
52. Leier CV Cardiomyoplasty: is it time to wrap it up ? J Am Coll Cardiol. 1996 ; 28 (5). 1101-1102.
53. Kass DA, Baughman KL, Pak PH, et al. Reverse remodeling from cardiomyoplasty in human heart failure. Circulation. 1995 ; 91 (9). 2314-2318.
54. Chaudhry PA, Mishima T., Sharov VG, et al. Passive epicardial containment prevents ventricular remodeling in heart failure. Ann Thorac Surg. 2000 ; 70 (4). 1275-1280.
55. Sabbah HN, Chaudhry PA, Paone G, et al. Passive ventricular constraint with Acorn prosthetic jacket prevents progressive left ventricuardilation and improves ejection fraction in dogs with moderate heart failure. J Am Coll Cardiol. 1999;33(2 suppl A):207A. 57
56. Sabbah HN, Sharov VG, Gupta RC, et al. Reversal of chronic molecular and cellular abnormalities due to heart failure by passive mechanical ventricular containment. Circ Res. 2003; 93(11):1095-1101.
57. Rastogi S., Gupta RC, Mishra S., Morita H., Tanhehco EJ, Sabbah HN Long-term therapy with the acorn cardiac support device normalizes gene expression of growth factors and gelatinases in dogs with heart failure. J Heart Lung Transplant. 2005 ; 24 (10). 1619-1625. (Pubitemid 41396462)
58. Saavedra WF, Tunin RS, Paolocci N., et al. Reverse remodeling and enhanced adrenergic reserve from passive external support in experimental dilated heart failure. J Am Coll Cardiol. 2002 ; 39 (12). 2069-2076.
59. Acker MA Clinical results with the Acorn cardiac restraint device with and without mitral valve surgery. Semin Thorac Cardiovasc Surg. 2005 ; 17 (4). 361-363.
60. Klodell CT Jr, Aranda JM Jr, McGiffin DC, et al. Worldwide surgical experience with the paracor HeartNet cardiac restraint device. J Thorac Cardiovasc Surg. 2008 ; 135 (1). 188-195.
61. Menicanti L., Di Donato M. The Dor Procedure: what has changed after fifteen years of clinical practice ? J Thorac Cardiovasc Surg. 2002 ; 124 (5). 886-890.
62. Athanasuleas CL, Stanley AW Jr, Buckberg GD, Dor V., DiDonato M., Blackstone EH Surgical anterior ventricular restoration (SAVER) in the dilated remodeled ventricle after anterior myocardial infarction. J Am Coll Cardiol. 2001 ; 37 (5). 1199-1209.
63. Jones RH, Velazquez EJ, Michler RE, et al. Coronary bypass surgery with or without surgical ventricular reconstruction. N Engl J Med. 2009 ; 360 (17). 1705-1717.